Literature DB >> 33822066

Development of COVIDVax Model to Estimate the Risk of SARS-CoV-2-Related Death Among 7.6 Million US Veterans for Use in Vaccination Prioritization.

George N Ioannou1,2, Pamela Green2, Vincent S Fan3, Jason A Dominitz1, Ann M O'Hare4, Lisa I Backus5, Emily Locke2, McKenna C Eastment6, Thomas F Osborne7,8, Nikolas G Ioannou9, Kristin Berry2.   

Abstract

Importance: A strategy that prioritizes individuals for SARS-CoV-2 vaccination according to their risk of SARS-CoV-2-related mortality would help minimize deaths during vaccine rollout. Objective: To develop a model that estimates the risk of SARS-CoV-2-related mortality among all enrollees of the US Department of Veterans Affairs (VA) health care system. Design, Setting, and Participants: This prognostic study used data from 7 635 064 individuals enrolled in the VA health care system as of May 21, 2020, to develop and internally validate a logistic regression model (COVIDVax) that predicted SARS-CoV-2-related death (n = 2422) during the observation period (May 21 to November 2, 2020) using baseline characteristics known to be associated with SARS-CoV-2-related mortality, extracted from the VA electronic health records (EHRs). The cohort was split into a training period (May 21 to September 30) and testing period (October 1 to November 2). Main Outcomes and Measures: SARS-CoV-2-related death, defined as death within 30 days of testing positive for SARS-CoV-2. VA EHR data streams were imported on a data integration platform to demonstrate that the model could be executed in real-time to produce dashboards with risk scores for all current VA enrollees.
Results: Of 7 635 064 individuals, the mean (SD) age was 66.2 (13.8) years, and most were men (7 051 912 [92.4%]) and White individuals (4 887 338 [64.0%]), with 1 116 435 (14.6%) Black individuals and 399 634 (5.2%) Hispanic individuals. From a starting pool of 16 potential predictors, 10 were included in the final COVIDVax model, as follows: sex, age, race, ethnicity, body mass index, Charlson Comorbidity Index, diabetes, chronic kidney disease, congestive heart failure, and Care Assessment Need score. The model exhibited excellent discrimination with area under the receiver operating characteristic curve (AUROC) of 85.3% (95% CI, 84.6%-86.1%), superior to the AUROC of using age alone to stratify risk (72.6%; 95% CI, 71.6%-73.6%). Assuming vaccination is 90% effective at preventing SARS-CoV-2-related death, using this model to prioritize vaccination was estimated to prevent 63.5% of deaths that would occur by the time 50% of VA enrollees are vaccinated, significantly higher than the estimate for prioritizing vaccination based on age (45.6%) or the US Centers for Disease Control and Prevention phases of vaccine allocation (41.1%). Conclusions and Relevance: In this prognostic study of all VA enrollees, prioritizing vaccination based on the COVIDVax model was estimated to prevent a large proportion of deaths expected to occur during vaccine rollout before sufficient herd immunity is achieved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33822066     DOI: 10.1001/jamanetworkopen.2021.4347

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  11 in total

1.  Predicting COVID-19 severity using major risk factors and received vaccines.

Authors:  Ariel Israel; Alejandro A Schäffer; Eugene Merzon; Ilan Green; Eli Magen; Avivit Golan-Cohen; Shlomo Vinker; Eytan Ruppin
Journal:  medRxiv       Date:  2022-01-03

2.  Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.

Authors:  George N Ioannou; Amy S B Bohnert; Ann M O'Hare; Edward J Boyko; Matthew L Maciejewski; Valerie A Smith; C Barrett Bowling; Elizabeth Viglianti; Theodore J Iwashyna; Denise M Hynes; Kristin Berry
Journal:  Ann Intern Med       Date:  2022-10-11       Impact factor: 51.598

3.  A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received.

Authors:  Ariel Israel; Alejandro A Schäffer; Eugene Merzon; Ilan Green; Eli Magen; Avivit Golan-Cohen; Shlomo Vinker; Eytan Ruppin
Journal:  Microorganisms       Date:  2022-06-16

4.  Evaluation of Vaccination Strategies to Compare Efficient and Equitable Vaccine Allocation by Race and Ethnicity Across Time.

Authors:  Patricia Kipnis; Lauren Soltesz; Gabriel J Escobar; Laura Myers; Vincent X Liu
Journal:  JAMA Health Forum       Date:  2021-08-20

5.  Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system.

Authors:  George N Ioannou; Pamela Green; Emily R Locke; Kristin Berry
Journal:  PLoS One       Date:  2021-12-01       Impact factor: 3.240

6.  Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from February 2020 to March 2021: A population-based cohort study.

Authors:  George N Ioannou; Jacqueline M Ferguson; Ann M O'Hare; Amy S B Bohnert; Lisa I Backus; Edward J Boyko; Thomas F Osborne; Matthew L Maciejewski; C Barrett Bowling; Denise M Hynes; Theodore J Iwashyna; Melody Saysana; Pamela Green; Kristin Berry
Journal:  PLoS Med       Date:  2021-10-21       Impact factor: 11.613

7.  Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.

Authors:  Adeel A Butt; Victor B Talisa; Peng Yan; Obaid S Shaikh; Saad B Omer; Florian B Mayr
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

8.  Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system.

Authors:  George N Ioannou; Emily R Locke; Pamela K Green; Kristin Berry
Journal:  EClinicalMedicine       Date:  2022-03-05

9.  Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2.

Authors:  A M O'Hare; K Berry; V S Fan; K Crothers; M C Eastment; J A Dominitz; J A Shah; P Green; E Locke; G N Ioannou
Journal:  BMC Geriatr       Date:  2021-07-06       Impact factor: 4.070

10.  Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population.

Authors:  Adeel A Butt; Peng Yan; Obaid S Shaikh; Florian B Mayr
Journal:  EClinicalMedicine       Date:  2021-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.